Approval of Spravato, granted following FDA priority review, was based on the results ... 7.6 percent of patients taking placebo. Spravato nasal spray is administered by the patient under the ...
Johnson & Johnson has priced its new Spravato nasal spray for treatment-resistant depression ... The Institute for Clinical and Economic Review (ICER) has published its final report on Spravato ...
This treatment is delivered through a nasal spray and relies not on ... The FDA fast-tracked Spravato’s approval through its Priority Review process after receiving results from a randomized ...
Hosted on MSN23d
FDA Clears Spravato For Monotherapy Depression TreatmentsThe Food and Drug Administration has approved Johnson & Johnson's nasal spray as a standalone treatment for severe forms of depression, officials said. The FDA granted approval to Spravato (esketamine ...
Johnson & Johnson has announced that the U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray as the first ... followed a priority review and was based on positive ...
The Food and Drug Administration recently expanded approval for Spravato, an antidepressant nasal spray used to treat ...
WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with ... Approval of Spravato, granted ...
WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults ... FDA priority review, was based on the results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback